Analyst Group

Analyst Group Comment on Circio’s Research Collaboration with Solid Biosciences

Källa: MFN
Positiv

Sammanfattning

Circio inleder ett forskningssamarbete med Solid Biosciences för att kombinera deras teknologier inom genterapi för genetiska hjärtsjukdomar. Samarbetet syftar till att adressera flaskhalsar gällande dosering och toxicitet.

Analys

Samarbetet med Solid Biosciences är en betydande förstärkning av Circios leveransnätverk. Genom att kombinera Circios circVec-plattform med Solids POLARIS-101 AAV-kapsid, adresserar man utmaningar med hög dosering, toxicitet och tillverkningskostnader inom systemisk genterapi för hjärtsjukdomar. Även om projektet är i ett tidigt skede utan finansiella villkor, är det en positiv signal att en klinisk utvecklare valt Circios teknologi.

Insikter

  • • Circios circVec-plattform visar potential för högre genuttryck jämfört med konventionella AAV-vektorer.
  • • Solid Biosciences POLARIS-101 kapsid är designad för att förbättra målinriktning till hjärtmuskeln.
  • • Samarbetet kan leda till framtida licensieringsmöjligheter.
Fundamental påverkan
Positiv

Samarbetet kan stärka Circios teknologiska position och öppna dörrar för framtida kommersialisering inom genterapi.

Omfattning: 4/10Liten påverkan
0 · Ingen påverkan10 · Avgörande påverkan

Poängen visar omfattning, inte förväntad kursrörelse.

Circio Holding ASA (“Circio” or “the Company”) announced, on the 11th of November 2026, a research collaboration with Nasdaq-listed Solid Biosciences Inc. (“Solid”) to combine Circio’s circVec expression platform with POLARIS-101, Solid’s proprietary next-generation AAV capsid, for systemic gene therapy in genetic heart disease. Under the agreement, Circio will generate constructs based on its latest generation 5 circVec design, which Solid will package using POLARIS-101 and its dual plasmid manufacturing platform. The parties will then jointly characterize and test the resulting vectors both in vitro and in vivo, with successful candidates evaluated further and advanced into preclinical development. No financial terms are disclosed.

Circio Holding ASA (“Circio” or “the Company”) announced, on the 11th of November 2026, a research collaboration with Nasdaq-listed Solid Biosciences Inc. (“Solid”) to combine Circio’s circVec expression platform with POLARIS-101, Solid’s proprietary next-generation AAV capsid, for systemic gene therapy in genetic heart disease. Under the agreement, Circio will generate constructs based on its latest generation 5 circVec design, which Solid will package using POLARIS-101 and its dual plasmid manufacturing platform. The parties will then jointly characterize and test the resulting vectors both in vitro and in vivo, with successful candidates evaluated further and advanced into preclinical development. No financial terms are disclosed.

In summary, Analyst Group considers the Solid Biosciences agreement one of the most substantive additions to Circio’s delivery network to date. High vector doses remain the central bottleneck in systemic cardiac gene therapy, driving both toxicity risk and manufacturing cost, and the collaboration addresses that constraint from two directions. Here, circVec 5.2, which has shown approx. 200-fold higher gene expression than conventional AAV vectors in heart, raises output per cell, while POLARIS-101, a capsid already dosed systemically in patients, is engineered to direct more of the dose to cardiac muscle and less to the liver. The work nevertheless sits at an early stage, carries no disclosed financial terms, and positions any successful candidate at the entry to preclinical development rather than near the clinic. Analyst Group still considers the signal meaningful already today, as circVec has been chosen as the expression component by a clinical-stage developer with cardiac programs of its own, a counterparty profile from which a licensing relationship could realistically develop over time.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.